NCT00004154View on ClinicalTrials.gov

Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

July 30, 1998

Primary Completion Date

March 1, 2005

Study Completion Date

March 1, 2005

Conditions
Bladder Cancer
Interventions
DRUG

Fenretinide

200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.

OTHER

Placebo

Two placebo capsules for 25 days of 28 day cycle.

Trial Locations (3)

77030

Baylor College of Medicine, Houston

98108

Veterans Affairs Medical Center - Seattle, Seattle

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00004154 - Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer | Biotech Hunter | Biotech Hunter